CD274 and non-small cell lung carcinoma: This study evaluated the cost-effectiveness of atezolizumab and pembrolizumab in comparison with chemotherapy in previously untreated stage IV NSCLC patients, and further sub-analyzed the cost-effectiveness in different PD-L1 expression levels (≥50% and ≥1%).